Comparative efficacy and toxicity of amikacin/carbenicillin versus gentamicin/carbenicillin in leukopenic patients: a randomized prospective trail
about
Tobramycin nephrotoxicity. A prospective clinical studyThe pharmaco -, population and evolutionary dynamics of multi-drug therapy: experiments with S. aureus and E. coli and computer simulationsIn vitro susceptibility of 104 clinical isolates of Haemophilus influenzae to moxalactam (LY127935), ampicillin, chloramphenicol, and ticarcillinMezlocillin for treatment of infections in cancer patientsComparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E testProspective randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic patients.Comparison of azlocillin, ceftizoxime, cefoxitin, and amikacin alone and in combination against Pseudomonas aeruginosa in a neutropenic-site rabbit modelAntimicrobial agent therapy for Pseudomonas aeruginosa.Rapid diagnosis of Pseudomonas aeruginosa urinary tract infections by radioimmunoassay.Aminoglycoside-induced hearing loss in humans.In vitro antibacterial activity of amikacin and ticarcillin, alone and in combination, against Pseudomonas aerurginosa.Bactericidal activity of ceftazidime in serum compared with that of ticarcillin combined with amikacin.Synergism at clinically attainable concentrations of aminoglycoside and beta-lactam antibiotics.Comparative in vitro synergistic activity of new beta-lactam antimicrobial agents and amikacin against Pseudomonas aeruginosa and Serratia marcescens.In vitro and in vivo studies of three antibiotic combinations against gram-negative bacteria and Staphylococcus aureus.Methodological variation in antibiotic synergy tests against enterococci.Empiric antibiotic therapy for granulocytopenic patients.
P2860
Q28328829-C51E4FD5-41FB-4EB8-8DE3-C9E662D75A46Q28485988-F410EFCF-1047-4743-B9DF-9CEE9F63775DQ33725629-2FF660EB-5108-42F8-B807-50B357AB38B8Q33730391-1166D103-44FA-468A-8FBE-CC11A0C4F3C3Q35126210-02331210-740A-4F83-B62F-EFDB3683D294Q35573306-08819848-2E7A-4FD4-9CAC-ADED1FDC9E3DQ35759586-EE09C7FC-3BA8-40B5-B1F4-47B6E3ABEEB7Q36756391-16B7DD56-CFD9-42C8-AF6F-FDBA97CD0DF7Q37313472-35DA0A6B-A88E-4B3C-B0B7-5CECAE7AC2F0Q38676819-4C37B5AA-86B6-4119-9CE0-79E71ED93BD1Q39611982-E85E93E3-1B7E-46A3-8189-0F77296046E2Q39833482-780B7604-B219-4621-9DDF-5A441E64B392Q39849094-B4812690-CD28-4B15-87E3-CA3E05BE784FQ39855592-967DE4FA-2D81-4F0D-B117-9ECACD91F545Q39855851-5DFAF93B-7ED7-4B88-A1D4-E9B40817783AQ40231640-47691F2B-AB67-4EDF-9529-D585F64C631EQ42945532-95C0DE31-A4A0-4E9E-A68C-42552CF7C34D
P2860
Comparative efficacy and toxicity of amikacin/carbenicillin versus gentamicin/carbenicillin in leukopenic patients: a randomized prospective trail
description
1977 nî lūn-bûn
@nan
1977 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1977 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1977年の論文
@ja
1977年論文
@yue
1977年論文
@zh-hant
1977年論文
@zh-hk
1977年論文
@zh-mo
1977年論文
@zh-tw
1977年论文
@wuu
name
Comparative efficacy and toxic ...... a randomized prospective trail
@ast
Comparative efficacy and toxic ...... a randomized prospective trail
@en
Comparative efficacy and toxic ...... a randomized prospective trail
@nl
type
label
Comparative efficacy and toxic ...... a randomized prospective trail
@ast
Comparative efficacy and toxic ...... a randomized prospective trail
@en
Comparative efficacy and toxic ...... a randomized prospective trail
@nl
prefLabel
Comparative efficacy and toxic ...... a randomized prospective trail
@ast
Comparative efficacy and toxic ...... a randomized prospective trail
@en
Comparative efficacy and toxic ...... a randomized prospective trail
@nl
P2093
P1476
Comparative efficacy and toxic ...... a randomized prospective trail
@en
P2093
D J Winston
R J Weinstein
W L Hewitt
P304
P407
P577
1977-06-01T00:00:00Z